BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Luo Y, Ohmori H, Fujii K, Moriwaka Y, Sasahira T, Kurihara M, Tatsumoto N, Sasaki T, Yamashita Y, Kuniyasu H. HMGB1 attenuates anti-metastatic defence of the liver in colorectal cancer. Eur J Cancer. 2010;46:791-799. [PMID: 20018503 DOI: 10.1016/j.ejca.2009.11.011] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Lin L, Zhong K, Sun Z, Wu G, Ding G. Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma. J Cancer Res Clin Oncol 2012;138:11-22. [DOI: 10.1007/s00432-011-1067-0] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.5] [Reference Citation Analysis]
2 Murakami T, Matsuyama R, Ueda M, Mochizuki Y, Homma Y, Kameda K, Yazawa K, Izumisawa Y, Fukushima T, Kamimukai N, Yoshida K, Kamiya N, Hoffman RM, Endo I. High-Mobility Group Box 1 expression predicts survival of patients after resection of adenocarcinoma of the ampulla of Vater. World J Surg Oncol 2019;17:140. [PMID: 31399104 DOI: 10.1186/s12957-019-1675-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
3 Pandolfi F, Altamura S, Frosali S, Conti P. Key Role of DAMP in Inflammation, Cancer, and Tissue Repair. Clin Ther 2016;38:1017-28. [PMID: 27021609 DOI: 10.1016/j.clinthera.2016.02.028] [Cited by in Crossref: 80] [Cited by in F6Publishing: 86] [Article Influence: 13.3] [Reference Citation Analysis]
4 Zhu J, Luo J, Li Y, Jia M, Wang Y, Huang Y, Ke S. HMGB1 induces human non-small cell lung cancer cell motility by activating integrin αvβ3/FAK through TLR4/NF-κB signaling pathway. Biochemical and Biophysical Research Communications 2016;480:522-7. [DOI: 10.1016/j.bbrc.2016.10.052] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
5 Cheng P, Ma Y, Gao Z, Duan L. High Mobility Group Box 1 (HMGB1) Predicts Invasion and Poor Prognosis of Glioblastoma Multiforme via Activating AKT Signaling in an Autocrine Pathway. Med Sci Monit 2018;24:8916-24. [PMID: 30531692 DOI: 10.12659/MSM.912104] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
6 Luo Y, Chihara Y, Fujimoto K, Sasahira T, Kuwada M, Fujiwara R, Fujii K, Ohmori H, Kuniyasu H. High mobility group box 1 released from necrotic cells enhances regrowth and metastasis of cancer cells that have survived chemotherapy. Eur J Cancer 2013;49:741-51. [PMID: 23040637 DOI: 10.1016/j.ejca.2012.09.016] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 5.9] [Reference Citation Analysis]
7 Cheng KJ, Alshawsh MA, Mejia Mohamed EH, Thavagnanam S, Sinniah A, Ibrahim ZA. HMGB1: an overview of its versatile roles in the pathogenesis of colorectal cancer.Cell Oncol (Dordr). 2020;43:177-193. [PMID: 31677065 DOI: 10.1007/s13402-019-00477-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
8 Le Bagge S, Fotheringham AK, Leung SS, Forbes JM. Targeting the receptor for advanced glycation end products (RAGE) in type 1 diabetes. Med Res Rev 2020;40:1200-19. [PMID: 32112452 DOI: 10.1002/med.21654] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
9 Paschos KA, Majeed AW, Bird NC. Natural history of hepatic metastases from colorectal cancer - pathobiological pathways with clinical significance. World J Gastroenterol 2014; 20(14): 3719-3737 [PMID: 24744570 DOI: 10.3748/wjg.v20.i14.3719] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
10 Peng RQ, Wu XJ, Ding Y, Li CY, Yu XJ, Zhang X, Pan ZZ, Wan DS, Zheng LM, Zeng YX, Zhang XS. Co-expression of nuclear and cytoplasmic HMGB1 is inversely associated with infiltration of CD45RO+ T cells and prognosis in patients with stage IIIB colon cancer. BMC Cancer 2010;10:496. [PMID: 20846416 DOI: 10.1186/1471-2407-10-496] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
11 Xu T, Jiang L, Wang Z. The progression of HMGB1-induced autophagy in cancer biology. Onco Targets Ther 2019;12:365-77. [PMID: 30643434 DOI: 10.2147/OTT.S185876] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
12 Tang CH, Keng YT, Liu JF. HMGB-1 induces cell motility and α5β1 integrin expression in human chondrosarcoma cells. Cancer Lett 2012;322:98-106. [PMID: 22361176 DOI: 10.1016/j.canlet.2012.02.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
13 Huilgol D, Venkataramani P, Nandi S, Bhattacharjee S. Transcription Factors That Govern Development and Disease: An Achilles Heel in Cancer. Genes (Basel) 2019;10:E794. [PMID: 31614829 DOI: 10.3390/genes10100794] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
14 Little JP, Simtchouk S, Schindler SM, Villanueva EB, Gill NE, Walker DG, Wolthers KR, Klegeris A. Mitochondrial transcription factor A (Tfam) is a pro-inflammatory extracellular signaling molecule recognized by brain microglia. Molecular and Cellular Neuroscience 2014;60:88-96. [DOI: 10.1016/j.mcn.2014.04.003] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 4.5] [Reference Citation Analysis]
15 Armstrong VS, Fitzgerald LW, Bathe OF. Cancer-Associated Muscle Wasting-Candidate Mechanisms and Molecular Pathways. Int J Mol Sci 2020;21:E9268. [PMID: 33291708 DOI: 10.3390/ijms21239268] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 He SJ, Cheng J, Feng X, Yu Y, Tian L, Huang Q. The dual role and therapeutic potential of high-mobility group box 1 in cancer. Oncotarget 2017;8:64534-50. [PMID: 28969092 DOI: 10.18632/oncotarget.17885] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 11.8] [Reference Citation Analysis]
17 Pilzweger C, Holdenrieder S. Circulating HMGB1 and RAGE as Clinical Biomarkers in Malignant and Autoimmune Diseases. Diagnostics (Basel) 2015;5:219-53. [PMID: 26854151 DOI: 10.3390/diagnostics5020219] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
18 Zhu L, Ren L, Chen Y, Fang J, Ge Z, Li X. Redox status of high-mobility group box 1 performs a dual role in angiogenesis of colorectal carcinoma. J Cell Mol Med 2015;19:2128-35. [PMID: 26099505 DOI: 10.1111/jcmm.12577] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
19 Li B, Jiang S, Zheng X, Ni B, Yang Y, Chen J, Chen K, Jiang L. Expression of the Inflammatory Molecule HMGB1 in Human Osteosarcoma and its Clinical Relevance. Eur J Inflamm 2013;11:61-73. [DOI: 10.1177/1721727x1301100107] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
20 Paschos KA, Majeed AW, Bird NC. Natural history of hepatic metastases from colorectal cancer--pathobiological pathways with clinical significance. World J Gastroenterol. 2014;20:3719-3737. [PMID: 24744570 DOI: 0.3748/wjg.v20.i14.3719] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Ohmori H, Luo Y, Kuniyasu H. Non-histone nuclear factor HMGB1 as a therapeutic target in colorectal cancer. Expert Opinion on Therapeutic Targets 2010;15:183-93. [DOI: 10.1517/14728222.2011.546785] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 3.7] [Reference Citation Analysis]
22 Li L, Liu H, Tao W, Wen S, Fu X, Yu S. Pharmacological Inhibition of HMGB1 Prevents Muscle Wasting. Front Pharmacol 2021;12:731386. [PMID: 34867338 DOI: 10.3389/fphar.2021.731386] [Reference Citation Analysis]
23 Zhang W, An F, Xia M, Zhan Q, Tian W, Jiao Y. Increased HMGB1 expression correlates with higher expression of c-IAP2 and pERK in colorectal cancer. Medicine (Baltimore) 2019;98:e14069. [PMID: 30653121 DOI: 10.1097/MD.0000000000014069] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
24 van Dijk DPJ, Krill M, Farshidfar F, Li T, Rensen SS, Olde Damink SWM, Dixon E, Sutherland FR, Ball CG, Mazurak VC, Baracos VE, Bathe OF. Host phenotype is associated with reduced survival independent of tumour biology in patients with colorectal liver metastases. J Cachexia Sarcopenia Muscle 2019;10:123-30. [PMID: 30378742 DOI: 10.1002/jcsm.12358] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]